These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25916862)

  • 1. Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications.
    Owen JG; Reisin E
    Curr Hypertens Rep; 2015 Jun; 17(6):558. PubMed ID: 25916862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary hypertension: obesity and the metabolic syndrome.
    Singer GM; Setaro JF
    J Clin Hypertens (Greenwich); 2008 Jul; 10(7):567-74. PubMed ID: 18607142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Beta-Blockers in the Treatment of Hypertension.
    Cruickshank JM
    Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
    Hall JE; do Carmo JM; da Silva AA; Wang Z; Hall ME
    Circ Res; 2015 Mar; 116(6):991-1006. PubMed ID: 25767285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of arterial hypertension in obese patients.
    Wenzel UO; Benndorf R; Lange S
    Semin Nephrol; 2013 Jan; 33(1):66-74. PubMed ID: 23374895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
    Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension in Metabolic Syndrome: Novel Insights.
    Katsimardou A; Imprialos K; Stavropoulos K; Sachinidis A; Doumas M; Athyros V
    Curr Hypertens Rev; 2020; 16(1):12-18. PubMed ID: 30987573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolic syndrome in hypertension: European society of hypertension position statement.
    Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
    J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for special populations: diabetes mellitus and the metabolic syndrome.
    Sowers JR
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):41S-45S. PubMed ID: 14625160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of antihypertensive drugs in obesity-related hypertension: a retrospective observational study in a cohort of patients from Southern Italy.
    Cataldi M; di Geronimo O; Trio R; Scotti A; Memoli A; Capone D; Guida B
    BMC Pharmacol Toxicol; 2016 Mar; 17():9. PubMed ID: 26980335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of hypertension in obesity].
    Scholze J; Sharma AM
    Herz; 2001 May; 26(3):209-21. PubMed ID: 11413801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of arterial hypertension in obese patients.
    Wenzel UO; Krebs C
    Curr Hypertens Rep; 2007 Dec; 9(6):491-7. PubMed ID: 18367013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
    Khan NA; Hemmelgarn B; Padwal R; Larochelle P; Mahon JL; Lewanczuk RZ; McAlister FA; Rabkin SW; Hill MD; Feldman RD; Schiffrin EL; Campbell NR; Logan AG; Arnold M; Moe G; Campbell TS; Milot A; Stone JA; Jones C; Leiter LA; Ogilvie RI; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; Burns KD; Ruzicka M; deChamplain J; Pylypchuk G; Gledhill N; Petrella R; Boulanger JM; Trudeau L; Hegele RA; Woo V; McFarlane P; Touyz RM; Tobe SW;
    Can J Cardiol; 2007 May; 23(7):539-50. PubMed ID: 17534460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology and treatment of obesity hypertension.
    Wofford MR; Hall JE
    Curr Pharm Des; 2004; 10(29):3621-37. PubMed ID: 15579059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A guide to the management of blood pressure in the diabetic hypertensive patient.
    Shammas NW; Sica DA; Toth PP
    Am J Cardiovasc Drugs; 2009; 9(3):149-62. PubMed ID: 19463021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.